No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
CN Stock MarketDetailed Quotes
000963 Huadong Medicine
- 27.72
- +0.44+1.61%
Market Closed Jul 12 15:00 CST
48.63BMarket Cap16.51P/E (TTM)
27.90High27.27Low121.01KlotVolume27.30Open27.28Pre Close333.69MTurnover0.69%Turnover Ratio17.13P/E (Static)1.75BShares45.8552wk High2.32P/B48.54BFloat Cap25.9652wk Low30.01Limit Up1.75BShs Float52.55Historical High24.55Limit Down2.31%Amplitude-3.03Historical Low0.58Dividend TTM27.58Avg Price65.17KlotAsk2.09%Div YieldTTM100Lot Size51.72KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Huadong Medicine (000963.SZ): HDM1002 is currently in Phase II clinical trials in China.
Huadong Medicine (000963.SZ) stated on the investor interaction platform on July 5th that the company will choose the overseas clinical development path according to the project situation in the future. HDM1002 is currently in phase II clinical research in China.
Huadong Medicine (000963.SZ): Baoling Health has products such as "Good Elements PQQ Collagen Peptide Drink".
On July 5th, Gelunhui reported that Huadong Medicine (000963.SZ) stated on their investor interaction platform that their subsidiary, Bailin Health, has products such as 'Shanyao PQQ Collagen Peptide Drink.'
Huadong Medicine's Unit Gets US FDA's Nod to Trial Tumor Drug
Huadong Medicine's (SHE:000963) unit, Hangzhou Sino-US Huadong Pharmaceutical, will conduct Phase I clinical trials on HDM2005 for injection in the US after receiving the approval of the country's Foo
Investors Don't See Light At End Of Huadong Medicine Co., Ltd's (SZSE:000963) Tunnel
Huadong Medicine Co., Ltd's (SZSE:000963) price-to-earnings (or "P/E") ratio of 16.7x might make it look like a buy right now compared to the market in China, where around half of the companies have P
Huadong Medicine (000963.SZ): HDM2005, the injectable drug used in China and the United States, has obtained the approval of FDA's new drug clinical trial.
On July 1st, Gelunhui reported that Huadong Medicine (000963.SZ) announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (hereinafter referred to as "Zhongmei Huadong"), received a notification from the U.S. Food and Drug Administration (FDA) that the clinical trial application for injection HDM2005 drugs declared by Zhongmei Huadong has been approved by the FDA and can conduct phase I clinical trials in the United States. Injected HDM2005 is a type 1 new biopharmaceutical with global intellectual property rights developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. It is a targeted receptor tyrosine.
Express News | Huadong Medicine - Hdm1002 Phase Ib Trial Shows Significant Weight Loss in 100Mg or Higher Dose Group
Comments
Despite Huadong Medicine's strong earnings outlook and rapid growth, its low P/E ratio suggests investor skepticism about future earnings volatility. The company also shows 1 warning sign in investment analysis.
Fewer Investors Than Expected Jumping On Huadong Medicine Co., Ltd (SZSE:000963) 1
Despite the short-term decrease in returns on capital, the growth in revenue and capital employed for Huadong Medicine is seen as promising. If these growth trends continue, the stock could perform well in the future.
Despite falling EPS, rising share price hint at the market valuing future potential. Positive sentiments may be due to steady revenue growth, indicating investor anticipation. Dividend payments over last 3 years contributed significantly with a 68% total shareholder return.
Core point
1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream
2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...
1. In the past three years, China's medical beauty industry has undergone earth-shaking changes, and non-surgical products occupy the mainstream
2. The brand is a marketing tool and a social contract for the legal entity to face society. Last year, it began to issue documents on supervising medical aesthetics, focusing on doctors' qualifications, marketing, and the capabilities of three types of ...
Read more
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
%Chg